ヒト胚性幹細胞市場：タイプ、用途、エンドユーザー別-2025-2030年の世界予測

ヒト胚性幹細胞市場は、2023年に8億4,835万米ドルと評価され、2024年には9億2,043万米ドルに達すると予測され、CAGR 8.98%で成長し、2030年には15億4,981万米ドルに達すると予測されています。

ヒト胚性幹細胞（hESC）は、あらゆる細胞型に分化可能なヒト初期胚由来の多能性幹細胞です。そのユニークな特性は、再生医療、創薬、発生生物学において極めて重要です。hESCの必要性は、特にパーキンソン病、糖尿病、心臓病などの疾患治療に革命をもたらす可能性にあります。これらの細胞は患者に特化した治療法を提供するため、毒物学的検査、遺伝子研究、個別化医療にも応用されます。エンドユーザーには、幹細胞研究に注力する研究機関、バイオテクノロジー企業、臨床研究機関などが含まれます。主な成長促進要因としては、再生医療の進歩、幹細胞研究に対する政府・民間資金の増加、革新的な治療ソリューションを必要とする慢性疾患の増加などが挙げられます。さらに、精密医療への関心の高まりは、hESCを用いた治療に有利な機会をもたらしています。しかし、hESCの供給源をめぐる倫理的な懸念や規制上のハードルは、大きな課題となっています。幹細胞の分化を制御する技術的限界や、hESCを用いた治療にかかる高コストも、市場の成長を阻害しています。倫理的な調達方法を開発し、分化技術を強化し、生産コストを削減することで、これらの課題を克服し、hESCの受容と応用を拡大する機会が存在します。この市場はまた、技術共有のための共同研究や、幹細胞の有用性に関する社会的認知の向上にも潜在力を秘めています。高度な治療ソリューションへの需要が高まる中、技術革新は極めて重要です。焦点となる分野は、細胞治療を改善するための遺伝子工学、より広範なアクセスを可能にするための製造規模の拡大、より優れた疾患モデリングのためのバイオインフォマティクスの改善などです。hESC市場はダイナミックであり、利害関係者が倫理的・規制的問題に対処し、革新的なソリューションを生み出し、個別化医療と再生治療に対する需要の進化に適応することで、大きく成長する態勢が整っています。

市場力学：急速に進化するヒト胚性幹細胞市場の主要市場インサイトを公開

ヒト胚性幹細胞市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 遺伝性疾患の急増
  • 疾患治療における幹細胞治療の有用性に関する消費者の意識の高まり
  • 再生医療に対する需要の高まり
• 市場抑制要因
  • 治療費の高騰
• 市場機会
  • ヒト胚性幹細胞における継続的な研究活動
  • 幹細胞治療の技術開発
• 市場の課題
  • 政府の厳しい規制

ポーターのファイブフォース：ヒト胚性幹細胞市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ヒト胚性幹細胞市場における外部からの影響の把握

外部マクロ環境要因は、ヒト胚性幹細胞市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ヒト胚性幹細胞市場における競合情勢の把握

ヒト胚性幹細胞市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスヒト胚性幹細胞市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ヒト胚性幹細胞市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ヒト胚性幹細胞市場における成功への道筋を描く

ヒト胚性幹細胞市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 遺伝性疾患の有病率の急増
    • 幹細胞の病気治療への有効性に関する消費者の認識の高まり
    • 再生医療の需要増加
  • 抑制要因
    • 治療費が高い
  • 機会
    • ヒト胚性幹細胞における進行中の調査活動
    • 幹細胞治療における技術開発
  • 課題
    • 政府の厳しい規則と規制
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ヒト胚性幹細胞市場：タイプ別

• 多能性幹細胞
• 全能性幹細胞
• 単能性幹細胞

第7章 ヒト胚性幹細胞市場：用途別

• 再生医療
• 幹細胞生物学調査
• 組織工学
• 毒性試験

第8章 ヒト胚性幹細胞市場：エンドユーザー別

• 臨床試験
• 調査

第9章 南北アメリカのヒト胚性幹細胞市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のヒト胚性幹細胞市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのヒト胚性幹細胞市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• Becton, Dickinson and Company
• Biotime, Inc
• CellGenix GmbH
• International Stem Cell Corporation
• Lineage Cell Therapeutics Inc.
• Lonza Group AG
• Merck KGaA
• Novo Nordisk A/S
• PeproTech Inc.
• Pfizer Inc.
• PromoCell GmbH
• Qiagen NV
• R&D Systems, Inc.
• Smith & Nephew PLC
• Stemcell Technologies Inc.
• Sumanas, Inc.
• Takara Bio Inc.
• Thermo Fisher Scientific, Inc.
• ViaCyte, Inc.

LIST OF FIGURES

• FIGURE 1. HUMAN EMBRYONIC STEM CELLS MARKET RESEARCH PROCESS
• FIGURE 2. HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HUMAN EMBRYONIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HUMAN EMBRYONIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HUMAN EMBRYONIC STEM CELLS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HUMAN EMBRYONIC STEM CELLS MARKET DYNAMICS
• TABLE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY PLURIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TOTIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY UNIPOTENT STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STEM CELL BIOLOGY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. CANADA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 48. CHINA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. INDIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. ITALY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. POLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. QATAR HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. HUMAN EMBRYONIC STEM CELLS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. HUMAN EMBRYONIC STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2023

The Human Embryonic Stem Cells Market was valued at USD 848.35 million in 2023, expected to reach USD 920.43 million in 2024, and is projected to grow at a CAGR of 8.98%, to USD 1,549.81 million by 2030.

Human Embryonic Stem Cells (hESCs) are pluripotent stem cells derived from early-stage human embryos capable of differentiating into any cell type. Their unique properties make them pivotal in regenerative medicine, drug discovery, and developmental biology. The necessity of hESCs lies in their potential to revolutionize disease treatment, particularly in conditions like Parkinson's, diabetes, and heart diseases, where they can help regenerate damaged tissues. Applications extend to toxicology testing, genetic research, and personalized medicine, as these cells offer patient-specific therapy avenues. End-users encompass institutes focusing on stem cell research, biotechnology companies, and clinical research organizations. Key growth drivers include advancements in regenerative medicine, increasing government and private funding for stem cell research, and rising prevalence of chronic diseases demanding innovative treatment solutions. Additionally, the growing interest in precision medicine opens lucrative opportunities for hESC-based therapies. However, ethical concerns surrounding the source of hESCs and regulatory hurdles present significant challenges. Technological limitations in controlling stem cell differentiation and high costs involved in hESC-based treatments also impede market growth. Opportunities exist in overcoming these challenges by developing ethical sourcing methods, enhancing differentiation techniques, and reducing production costs, thus widening the acceptance and application of hESCs. The market also holds potential in collaborations for technology sharing and increasing public awareness regarding stem cell benefits. With the growing demand for advanced therapeutic solutions, innovation is critical. Focus areas should include genetic engineering to improve cell therapies, upscaling manufacturing for broader access, and improving bioinformatics for better disease modeling. The hESC market is dynamic and poised for substantial growth as stakeholders address ethical and regulatory issues, create innovative solutions, and adapt to the evolving demand for personalized medicine and regenerative therapies.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Human Embryonic Stem Cells Market

The Human Embryonic Stem Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Surge in the prevalence of genetic disorders
  • Growing awareness among consumers about the stem cell therapeutic potency for disease treatment
  • Increasing demand for the regenerative medicines
• Market Restraints
  • High cost of treatment
• Market Opportunities
  • Ongoing research activities in the human embryonic stem cells
  • Technological development in the stem cell therapy
• Market Challenges
  • Strict rules and regulations of the government

Porter's Five Forces: A Strategic Tool for Navigating the Human Embryonic Stem Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Human Embryonic Stem Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Human Embryonic Stem Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Human Embryonic Stem Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Human Embryonic Stem Cells Market

A detailed market share analysis in the Human Embryonic Stem Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Human Embryonic Stem Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Human Embryonic Stem Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Human Embryonic Stem Cells Market

A strategic analysis of the Human Embryonic Stem Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Human Embryonic Stem Cells Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Becton, Dickinson and Company, Biotime, Inc, CellGenix GmbH, International Stem Cell Corporation, Lineage Cell Therapeutics Inc., Lonza Group AG, Merck KGaA, Novo Nordisk A/S, PeproTech Inc., Pfizer Inc., PromoCell GmbH, Qiagen NV, R&D Systems, Inc., Smith & Nephew PLC, Stemcell Technologies Inc., Sumanas, Inc., Takara Bio Inc., Thermo Fisher Scientific, Inc., and ViaCyte, Inc..

Market Segmentation & Coverage

This research report categorizes the Human Embryonic Stem Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Pluripotent Stem Cells, Totipotent Stem Cells, and Unipotent Stem Cells.
• Based on Application, market is studied across Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing.
• Based on End-User, market is studied across Clinical Trials and Research.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surge in the prevalence of genetic disorders
    • 5.1.1.2. Growing awareness among consumers about the stem cell therapeutic potency for disease treatment
    • 5.1.1.3. Increasing demand for the regenerative medicines
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing research activities in the human embryonic stem cells
    • 5.1.3.2. Technological development in the stem cell therapy
  • 5.1.4. Challenges
    • 5.1.4.1. Strict rules and regulations of the government
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Human Embryonic Stem Cells Market, by Type

• 6.1. Introduction
• 6.2. Pluripotent Stem Cells
• 6.3. Totipotent Stem Cells
• 6.4. Unipotent Stem Cells

7. Human Embryonic Stem Cells Market, by Application

• 7.1. Introduction
• 7.2. Regenerative Medicine
• 7.3. Stem Cell Biology Research
• 7.4. Tissue Engineering
• 7.5. Toxicology Testing

8. Human Embryonic Stem Cells Market, by End-User

• 8.1. Introduction
• 8.2. Clinical Trials
• 8.3. Research

9. Americas Human Embryonic Stem Cells Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Human Embryonic Stem Cells Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Human Embryonic Stem Cells Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. Becton, Dickinson and Company
• 3. Biotime, Inc
• 4. CellGenix GmbH
• 5. International Stem Cell Corporation
• 6. Lineage Cell Therapeutics Inc.
• 7. Lonza Group AG
• 8. Merck KGaA
• 9. Novo Nordisk A/S
• 10. PeproTech Inc.
• 11. Pfizer Inc.
• 12. PromoCell GmbH
• 13. Qiagen NV
• 14. R&D Systems, Inc.
• 15. Smith & Nephew PLC
• 16. Stemcell Technologies Inc.
• 17. Sumanas, Inc.
• 18. Takara Bio Inc.
• 19. Thermo Fisher Scientific, Inc.
• 20. ViaCyte, Inc.